Our Phase 2 study is designed to investigate the safety, tolerability, pharmacokinetics, and efficacy of multiple doses of elarekibep, a promising drug candidate being developed to treat asthma. Elarekibep will be administered by oral inhalation to subjects with moderate asthma.
Our Phase 1 study is designed to investigate the safety, tolerability, and pharmacokinetics of PRS-220, a drug candidate being developed to treat IPF.
This global, open-label phase 1/2 dose escalation study is evaluating the safety, tolerability, potential optimal dosage, and potential anti-tumor activity of PRS-344/S095012 in patients with advanced solid tumors whose cancer progressed on standard-of-care treatment.
